Revenue (Tables)

6 Months Ended

Dec. 31, 2018

Revenue From Contract With Customer [Abstract]

Composition of Total Revenue by Product and U.S versus Rest of World

The following tables present detail regarding the composition of the Company’s total revenue by product and U.S. versus rest of world, “RoW”:

	Three months ended December 31,
	2018						2017
(In millions)	U.S.		RoW		Total		U.S.		RoW		Total
Molecular diagnostic revenues:
Hereditary Cancer Testing	$	123.4	$	3.3	$	126.7	$	119.6	$	2.6	$	122.2
GeneSight		24.0		—		24.0		31.7		—		31.7
Prenatal		31.2		—		31.2		—		—		—
VectraDA		11.8		—		11.8		11.1		—		11.1
Prolaris		6.1		—		6.1		4.2		—		4.2
EndoPredict		0.4		1.8		2.2		0.1		1.9		2.0
Other		0.7		0.3		1.0		1.7		0.2		1.9
Total molecular diagnostic revenue		197.6		5.4		203.0		168.4		4.7		173.1
Pharmaceutical and clinical service revenue		8.2		5.6		13.8		8.9		5.9		14.8
Total revenue	$	205.8	$	11.0	$	216.8	$	177.3	$	10.6	$	187.9

	Six months ended December 31,
	2018						2017
(In millions)	U.S.		RoW		Total		U.S.		RoW		Total
Molecular diagnostic revenues:
Hereditary Cancer Testing	$	237.0	$	6.1	$	243.1	$	234.2	$	5.0	$	239.2
GeneSight		53.2		—		53.2		60.5		—		60.5
Prenatal		49.3		—		49.3		—		—		—
VectraDA		24.8		—		24.8		25.1		—		25.1
Prolaris		12.3		—		12.3		8.1		—		8.1
EndoPredict		0.7		3.9		4.6		0.1		3.7		3.8
Other		4.4		0.3		4.7		3.5		0.3		3.8
Total molecular diagnostic revenue		381.7		10.3		392.0		331.5		9.0		340.5
Pharmaceutical and clinical service revenue		15.8		11.3		27.1		15.2		11.0		26.2
Total revenue	$	397.5	$	21.6	$	419.1	$	346.7	$	20.0	$	366.7

Reconciliation of Deferred Revenue Balances

A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:

	Six months ended
	December 31,
	2018			2017
Deferred revenue - beginning balance	$	2.6		$	2.6
Revenue recognized		(2.6	)		(10.3	)
Prepayments		2.4			11.1
Deferred revenue - Ending Balance	$	2.4		$	3.4